Today: 30 April 2026
Browse Category

NASDAQ:CGON 11 January 2026 - 12 January 2026

CG Oncology stock (CGON) jumps 29% on faster Phase 3 timeline — what to watch next week

CG Oncology stock (CGON) jumps 29% on faster Phase 3 timeline — what to watch next week

CG Oncology shares surged 29.3% to $54.20 after the company moved up its Phase 3 PIVOT-006 trial timeline, now expecting topline results in early 2026. Trading volume reached 7 million shares. Analysts raised price targets following the update and ahead of the JPMorgan Healthcare Conference. The trial enrolls over 360 bladder cancer patients and measures recurrence-free survival.
12 January 2026
··
CG Oncology stock (CGON) jumps 29% on faster PIVOT-006 Phase 3 readout — what to watch next

CG Oncology stock (CGON) jumps 29% on faster PIVOT-006 Phase 3 readout — what to watch next

CG Oncology shares surged 29% Friday to $54.20 after the company moved up its Phase 3 PIVOT-006 data release to early 2026. Morgan Stanley raised its price target to $93 and increased the program’s success probability to 70%. The company cited faster enrollment and no severe adverse events in recent data. CG Oncology will present at the J.P. Morgan Healthcare Conference on January 15.
11 January 2026
·
CG Oncology stock jumps 29% on faster Phase 3 PIVOT-006 data clock — what to watch next

CG Oncology stock jumps 29% on faster Phase 3 PIVOT-006 data clock — what to watch next

CG Oncology shares jumped nearly 29% Friday, closing at $54.20, after the company said topline Phase 3 trial data for its bladder cancer therapy will arrive in the first half of 2026, almost a year early. Morgan Stanley raised its price target to $93, citing the accelerated timeline. The PIVOT-006 trial enrolled over 360 patients at more than 90 sites.
11 January 2026
··

Stock Market Today

  • Stocks Mixed as Lower Oil Prices Support Market, Mega-Cap Tech Show Divergent Earnings
    April 30, 2026, 12:47 PM EDT. The S&P 500 edged up +0.08% and Dow Jones gained +0.73%, while Nasdaq 100 slipped -0.18%. Alphabet and Qualcomm's strong earnings lifted sentiment, with Alphabet surging +5% on revenue of $94.57 billion surpassing estimates. Qualcomm rose over +6% after better-than-expected Q2 results. However, Meta Platforms dropped more than -9% after a higher capital expenditure forecast. Microsoft slid over -3% amid growth concerns for Azure cloud despite beating earnings. Lower crude oil prices, down over -1% from three-week highs due to economic growth worries, helped ease inflation expectations and bond yields, supporting stocks. The 10-year Treasury yield fell 4 basis points to 4.39%. Mixed U.S. economic data included a 57-year low in weekly jobless claims and a softer Q1 GDP growth rate of +2.0%, below forecasts, illustrating ongoing economic uncertainty.

Latest article

Hertz Stock Surges on Uber Robotaxi Deal as Oro Mobility Steps Out of the Shadows

Hertz Stock Surges on Uber Robotaxi Deal as Oro Mobility Steps Out of the Shadows

30 April 2026
Hertz shares surged over 20% Thursday after it launched Oro Mobility, an affiliate set to manage Uber’s robotaxi and human-driven fleets in key U.S. markets. Oro will support Uber’s autonomous program with Lucid vehicles using Nuro self-driving tech, starting in the San Francisco Bay Area later this year. Hertz traded at $6.80, up $1.20; Uber fell 38 cents to $74.09. Hertz reports first-quarter results May 7.
Xerox Holdings Stock Soars After Q1 Revenue Beat, but the Lexmark Bill Is Still Showing

Xerox Holdings Stock Soars After Q1 Revenue Beat, but the Lexmark Bill Is Still Showing

30 April 2026
Xerox shares surged 43% Thursday after first-quarter revenue hit $1.85 billion, topping forecasts, driven by the Lexmark acquisition. The company posted a net loss of $105 million and an adjusted loss of 43 cents per share, wider than expected. Print segment revenue jumped 31%, while IT Solutions fell 5%. Xerox reaffirmed its 2026 outlook but reported higher interest expenses tied to acquisition debt.
Go toTop